Biothera unveils updated data from Phase 2 mTNBC trial at SABCS
Category: #health  By Mateen Dalal  Date: 2019-12-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biothera unveils updated data from Phase 2 mTNBC trial at SABCS

Biothera Pharmaceuticals, Inc., a renowned Minnesota based biotechnology company, reportedly announced that clinical benefit data and updated response from its Phase 2 study in chemo-refractory mTNBC (metastatic triple negative breast cancer) patients would be presented in a Spotlight Session during the 2019 San Antonio Breast Cancer Symposium (SABCS).

The Phase 2 study evaluates Biothera’s Imprime PGG, which is a systematically delivered dectin receptor triggering anti-cancer immune responses, with the anti-PD-1 therapy developed by Merck, KEYTRUDA® (pembrolizumab). The participants of the study were not treated earlier using immune checkpoint inhibitors. They also were identified as positive biomarker for Imprime PGG therapy.

Jeremy Graff, Ph.D., President and Chief Scientific Officer, Biothera Pharmaceuticals, reportedly stated that the clinical data showed compelling evidence from the combination of KEYTRUDA and Imprime PGG in chemo refractory mTNBC patients. Graff further added that the translational data not just delivers proof of concept at the cellular and molecular level, but also offers valuable insights regarding the next steps for clinical development of Imprime PGG.

Latest data from IMPRIME 1 showcased at SABCS depicted 15.9% overall response rate in mTNBC patients that were treated with the combination of KEYTRUDA and Imprime PGG.

Most of the patients showed target lesion stabilization or reduction. The discontinuation of treatment frequently resulted from increase in non-target lesion or new lesions, even when target lesions were stable or shrinking. Patients with such mixed response pattern showed an overall increase in survival.
 

About Biothera Pharmaceuticals:

Biothera Pharmaceuticals is a renowned biotechnology company headquartered in Minnesota. The firm is committed in developing CPIs, or immune checkpoint inhibitors in combination with Imprime PGG in multiple Phase 2 cancer indications. Its focus is on population of patients and types of tumor wherein single agent CPI therapy provides limited benefits. The types of tumor include non-small cell lung cancer, metastatic triple negative breast cancer, CPI-failed advanced melanoma and colorectal cancer.

 

Source credit: https://www.biothera.com/biothera-pharmaceuticals-presents-updated-phase-2-data-for-chemo-refractory-triple-negative-breast-cancer-patients-at-san-antonio-breast-cancer-symposium/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

PayPal buys Happy Returns to strengthen reverse logistics system
PayPal buys Happy Returns to strengthen reverse logistics system
By Mateen Dalal

U.S. based digital payments platform, PayPal, an online payment system entity has announced the purchase of Happy Returns- a returns solution firm that provides online buyers access to simplified ways to return unwanted merchandise to retailers; elim...

YOP officially unveils YOP app to ease access to DeFi for the masses
YOP officially unveils YOP app to ease access to DeFi for the masses
By Mateen Dalal

Yield Optimization Platform and Protocol (YOP) recently declared its official launch of YOP application; the first all-in-one mobile app which makes it quite easier for everyone to access DeFi. The V0 version of the app is now available for early acc...

Singapore to create second national supercomputer with more on roadmap
Singapore to create second national supercomputer with more on roadmap
By Mateen Dalal

Following its success of the first supercomputer system, Singapore is set to build its upcoming second supercomputer system in an attempt to strengthen the local research community, offering 8X more computing capacity than its previous model. The sy...